Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, Bouzas L F, Confer D, Greinix H, Horowitz M, Iida M, Lipton J, Mohty M, Novitzky N, Nunez J, Passweg J, Pasquini M C, Kodera Y, Apperley J, Seber A, Gratwohl A
The Worldwide Network of Blood and Marrow Transplantation (WBMT) Transplant Activity Survey Office, University Hospital Basel, Basel, Switzerland.
Department of Hematology-Oncology, University Hospital, Leipzig, Germany.
Bone Marrow Transplant. 2016 Jun;51(6):778-85. doi: 10.1038/bmt.2016.18. Epub 2016 Feb 22.
Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through their regional transplant organizations were analyzed by main indication, donor type and stem cell source for the year 2012. With transplant rates ranging from 0.1 to 1001 per 10 million inhabitants, more HSCTs were registered from unrelated 16 433 donors than related 15 493 donors. Grafts were collected from peripheral blood (66%), bone marrow (24%; mainly non-malignant disorders) and cord blood (10%). Compared with 2006, an increase of 46% total (57% allogeneic and 38% autologous) was observed. Growth was due to an increase in reporting teams (18%) and median transplant activity/team (from 38 to 48 HSCTs/team). An increase of 167% was noted in mismatched/haploidentical family HSCT. A Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis revealed the global perspective of WBMT to be its major strength and identified potential to be the key professional body for patients and authorities. The limited data collection remains its major weakness and threat. In conclusion, global HSCT grows over the years without plateauing (allogeneic>autologous) and at different rates in the four World Health Organization regions. Major increases were observed in allogeneic, haploidentical HSCT and, to a lesser extent, in cord blood transplantation.
对来自77个国家的1566个团队收集并通过其区域移植组织报告的68146例造血干细胞移植（HSCT）（53%为自体移植，47%为异体移植）数据，按2012年的主要适应症、供体类型和干细胞来源进行了分析。移植率从每1000万居民0.1例至1001例不等，登记的来自非亲属供体（16433例）的HSCT比亲属供体（15493例）更多。移植物采集自外周血（66%）、骨髓（24%；主要用于非恶性疾病）和脐血（10%）。与2006年相比，观察到总数增加了46%（异体移植增加57%，自体移植增加38%）。增长归因于报告团队增加（18%）以及每个团队的移植活动中位数（从每个团队38例HSCT增至48例）。错配/单倍体相合的家族性HSCT增加了167%。优势、劣势、机会、威胁（SWOT）分析显示，世界骨髓移植协会（WBMT）的全球视野是其主要优势，并确定其有潜力成为面向患者和当局的关键专业机构。数据收集有限仍然是其主要劣势和威胁。总之，多年来全球HSCT持续增长且无平稳期（异体移植>自体移植），在世界卫生组织的四个区域以不同速率增长。异体移植、单倍体相合HSCT以及程度较轻的脐血移植均有显著增加。
